Proteflazid® effectiveness for prevention and treatment of acute viral respiratory infections in the conditions of COVID-19.

Unlabelled: The original antiviral drug Proteflazid® has been used in clinical practice since the early 2000s for the etiotropic treatment of acute respiratory viral diseases, due to its property of blocking viral RNA and DNA polymerases. Considering that at the beginning of the global COVID- 19 pandemic, caused by RNA-containing virus of SARS-CoV-2 species in 2020, the ability of the drug active substance to inhibit the activity of 3CL- protease of the SARS-CoV-2 coronavirus was shown by molecular docking and, subsequently, to confirm the property of the active substance to block the reproduction of the SARS-CoV-2 virus in cell cultures in vitro. It was extremely important to test the effectiveness of the drug Proteflazid, drops for the prevention and treatment of COVID-19 disease at "off labell use".

Analysis of the clinical trial results of the flavonoid effects on some cellular immunity indicators in children and adults.

Unlabelled: In the scope of this paper, an analysis of the clinical trial results assessing the clinical and immunological efficacy of the effects of flavonoids on some indicators of immunity in children and adults is given.

Aim: The aim of the study was to evaluate the effects of flavonoids on the cellular component of the immune system in children and adults with viral and viral-bacterial diseases by using meta-analysis and statistical analysis of the clinical findings.

Materials And Methods: The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 412 children and 15 sources involving 1493 adult patients during the period from 2003 to 2017.

Proteflazid®: outcome analysis of clinical trials studying the impact of human herpesvirus infection on some cellular immunity indicators and gestation course in women.

Unlabelled: An outcome analysis of the clinical trials evaluating the clinical and immunological efficacy of the drug Proteflazid® in the treatment of diseases associated with herpesvirus infection in pregnant women is presented.

Aim: Objective of the study was to evaluate the effects of Proteflazid® on the cellular component of the immune system and gestation course in women with HHV infection by using meta-analysis and statistical analysis (based on Student's t-test) of the clinical findings.

Materials And Methods: The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 234 pregnant women during the period from 2003 to 2012.